August 23, 2017 — Xconomy Boston — The investment arm of biotech giant Amgen has led a new $6 million round of funding in GNS Healthcare, CEO Colin Hill tells Xconomy.
Amgen Ventures’ new investment is a part of the company’s Series C financing round, which now totals $23 million, says Hill, who is also GNS’s chairman and co-founder. Cambridge, MA-based GNS has raised $38 million in total investment capital to date. Alexandria Real Estate Equities also participated in the latest add-on investment.
Read more here.